Francisco Morís

2.9k total citations
84 papers, 2.2k citations indexed

About

Francisco Morís is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Francisco Morís has authored 84 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Molecular Biology, 29 papers in Organic Chemistry and 19 papers in Oncology. Recurrent topics in Francisco Morís's work include Enzyme Catalysis and Immobilization (20 papers), Microbial Natural Products and Biosynthesis (14 papers) and Carbohydrate Chemistry and Synthesis (11 papers). Francisco Morís is often cited by papers focused on Enzyme Catalysis and Immobilization (20 papers), Microbial Natural Products and Biosynthesis (14 papers) and Carbohydrate Chemistry and Synthesis (11 papers). Francisco Morís collaborates with scholars based in Spain, Germany and Austria. Francisco Morís's co-authors include Javier González‐Sabín, Nicolás Ríos‐Lombardía, Vicente Gotor, Cármen Méndez, Joaquín García‐Álvarez, José A. Salas, Alfredo F. Braña, Paula Costales, María J. Rodríguez‐Álvarez and María Carmen Collado and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Francisco Morís

84 papers receiving 2.2k citations

Peers

Countries citing papers authored by Francisco Morís

Since Specialization

Citations

This map shows the geographic impact of Francisco Morís's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francisco Morís with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francisco Morís more than expected).

Fields of papers citing papers by Francisco Morís

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francisco Morís. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francisco Morís. The network helps show where Francisco Morís may publish in the future.

Co-authorship network of co-authors of Francisco Morís

This figure shows the co-authorship network connecting the top 25 collaborators of Francisco Morís. A scholar is included among the top collaborators of Francisco Morís based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francisco Morís. Francisco Morís is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting the SP/KLF Transcriptional Regulatory Network Synergizes with HDAC Inhibition to Impede Progression of H3K27M Diffuse Intrinsic Pontine Glioma 2025 ·Cancer Research ·Yu Kong, (unknown), Renwei Jing, (unknown), (unknown), Yingying Zhao, Ye Yuan, (unknown), Yu Sun, (unknown), (unknown), (unknown), (unknown), Lei Cao, (unknown), Dawei Huo, Shao‐Kai Sun, Francisco Morís, Yujie Tang, Xudong Wu	1
2	Characterization of a selective, iron-chelating antifungal compound that disrupts fungal metabolism and synergizes with fluconazole 2024 ·Microbiology Spectrum ·(unknown), Lucía Ramos-Alonso, Javier González‐Sabín, Nicolás Ríos‐Lombardía, Nuria Trevijano‐Contador, (unknown), (unknown), Francisco Morís, Óscar Zaragoza, Pierre Chymkowitch, Ignacio García, Jorrit M. Enserink	4
3	Understanding the Preclinical Efficacy of Antibody–Drug Conjugates 2024 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), (unknown), (unknown), Emiliano Calvo, Víctor Moreno, Francisco Morís, Pedro Pérez‐Segura, Balázs Győrffy, Atanasio Pandiella, Alberto Ocaña	2
4	Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned 2023 ·Journal of Hematology & Oncology ·(unknown), (unknown), (unknown), Cristina Nieto‐Jiménez, (unknown), (unknown), Emiliano Calvo, Pedro Pérez‐Segura, Víctor Moreno, Francisco Morís, Alberto Ocaña	26
5	The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia 2022 ·Cancers ·Belén López‐Millán, Paula Costales, Francisco Gutiérrez‐Agüera, Rafael Díaz de la Guardia, Heleia Roca-Ho, Meritxell Vinyoles, (unknown), Rémi Safi, Julio Castaño, Paola Romecín, Manuel Ramı́rez, Eduardo Anguita, Irmela Jeremias, Lurdes Zamora, Juan Carlos Rodríguez‐Manzaneque, Clara Bueno, Francisco Morís, Pablo Menéndez	2
6	Genetic Engineering in Combination with Semi‐Synthesis Leads to a New Route for Gram‐Scale Production of the Immunosuppressive Natural Product Brasilicardin A 2021 ·Angewandte Chemie International Edition ·(unknown), (unknown), (unknown), (unknown), Paula Costales, Luz Elena Núñez, Jesús Cortés, Francisco Morís, (unknown), (unknown), Bertolt Gust, Mirna L.M. Rodriguez, (unknown), Bernd Jandeleit, Jolanta Zakrzewska‐Czerwińska, Wolfgang Wohlleben, Evi Stegmann, Pierre Koch, Cármen Méndez, Harald Gross	13
7	Deep eutectic solvent-catalyzed Meyer–Schuster rearrangement of propargylic alcohols under mild and bench reaction conditions 2020 ·Chemical Communications ·Nicolás Ríos‐Lombardía, Luciana Cicco, (unknown), (unknown), Francisco Morís, Vito Capriati, Joaquín García‐Álvarez, Javier González‐Sabín	18
8	Combination of organocatalytic oxidation of alcohols and organolithium chemistry (RLi) in aqueous media, at room temperature and under aerobic conditions 2020 ·Chemical Communications ·David Elorriaga, María J. Rodríguez‐Álvarez, Nicolás Ríos‐Lombardía, Francisco Morís, Alejandro Presa Soto, Javier González‐Sabín, Eva Hevia, Joaquín García‐Álvarez	18
9	Chemoenzymatic Synthesis of Sertraline 2019 ·European Journal of Organic Chemistry ·Lisa Marx, (unknown), Philipp Süss, Matthias Höhne, Francisco Morís, (unknown), Per Berglund	14
10	One‐pot Synthesis of 4‐Aminocyclohexanol Isomers by Combining a Keto Reductase and an Amine Transaminase 2019 ·ChemCatChem ·(unknown), (unknown), Francisco Morís, (unknown), (unknown), (unknown), Sebastian Günther, Philipp Süss, Matthias Höhne	7
11	Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia 2018 ·Molecular Cancer Therapeutics ·(unknown), Paula Costales, Isaac Antolı́n, (unknown), (unknown), (unknown), Jhudit Pérez‐Escuredo, (unknown), Ana M. Sánchez‐Sánchez, Elisa Luño, Carmen Rodrı́guez, Vanesa Martı́n, Francisco Morís	19
12	Programming cascade reactions interfacing biocatalysis with transition-metal catalysis in Deep Eutectic Solvents as biorenewable reaction media 2018 ·Green Chemistry ·Luciana Cicco, Nicolás Ríos‐Lombardía, María J. Rodríguez‐Álvarez, Francisco Morís, Filippo Maria Perna, Vito Capriati, Joaquín García‐Álvarez, Javier González‐Sabín	89
13	Increased heterologous production of the antitumoral polyketide mithramycin a by engineered Streptomyces lividans TK24 strains (vol 102, pg 857, 2018) 2018 ·Applied Microbiology and Biotechnology ·(unknown), (unknown), Dagmar Homerová, (unknown), Lubomira Feckova, Bronislava Řežuchová, (unknown), Nuria Menéndez, Francisco Morís, Jesús Cortés, Ján Kormanec	4
14	Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer 2018 ·European Urology Oncology ·Dheeraj Shinde, Domenico Albino, (unknown), (unknown), Sarah N. Mapelli, Gianluca Civenni, (unknown), Jessica Merulla, Jhudit Pérez‐Escuredo, Paula Costales, Francisco Morís, Carlo V. Catapano, Giuseppina M. Carbone	9
15	Combination of Metal-Catalyzed Cycloisomerizations and Biocatalysis in Aqueous Media: Asymmetric Construction of Chiral Alcohols, Lactones, and γ-Hydroxy-Carbonyl Compounds 2017 ·ACS Catalysis ·María J. Rodríguez‐Álvarez, Nicolás Ríos‐Lombardía, (unknown), (unknown), Francisco Morís, Victorio Cadierno, Joaquín García‐Álvarez, Javier González‐Sabín	47
16	EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB 2016 ·Molecular Cancer Therapeutics ·Gianluca Civenni, Nicole Longoni, Paula Costales, (unknown), (unknown), Domenico Albino, Luz Elena Núñez, Francisco Morís, Giuseppina M. Carbone, Carlo V. Catapano	36
17	Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor 2016 ·Clinical Cancer Research ·Christy Osgood, (unknown), (unknown), Susan M. Kitchen-Goosen, (unknown), (unknown), Girma M. Woldemichael, Min He, Savita Sankar, Stephen L. Lessnick, Min H. Kang, Malcolm A. Smith, Lisa Turner, Zachary Madaj, Mary E. Winn, (unknown), Javier González‐Sabín, Lee J. Helman, Francisco Morís, Patrick J. Grohar	57
18	Aldh1 Expression and Activity Increase During Tumor Evolution in Sarcoma Cancer Stem Cell Populations 2016 ·Scientific Reports ·Lucia Martínez-Cruzado, Juan Tornín, Laura Santos, Aida Rodríguez, Javier Garcı́a-Castro, Francisco Morís, René Rodrı́guez	41
19	Genome-Wide Modulation of Gene Transcription in Ovarian Carcinoma Cells by a New Mithramycin Analogue 2014 ·PLoS ONE ·Carolina Vizcaíno, (unknown), Francisco Morís, José Portugal	16
20	The chromomycin CmmA acetyltransferase: a membrane‐bound enzyme as a tool for increasing structural diversity of the antitumour mithramycin 2010 ·Microbial Biotechnology ·Beatriz García, Javier González‐Sabín, Nuria Menéndez, Alfredo F. Braña, Luz Elena Núñez, Francisco Morís, José A. Salas, Cármen Méndez	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact